Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology to co-develop VIR-5500 with Astellas; $335 million upfront and near-term payments

Mixed Impact 4 of 5 product/contract Written later

Vir Biotechnology agreed with Astellas on a global collaboration to co-develop and co-commercialize VIR-5500, a Phase 1 prostate cancer candidate, with closing subject to U.S. antitrust clearance. The same day, the company reported 2025 results: full-year revenue fell to $68.6 million while the full-year net loss narrowed to $438.0 million.

Key points

  • Vir to receive $335 million in upfront and near-term milestone payments, including $240 million in cash, a $75 million equity investment and a $20 million milestone
  • Astellas agreed to buy 7,239,382 shares at $10.36 per share, a 50% premium to the 30-day volume weighted average price as of February 17, 2026
  • Vir is eligible for up to $1.37 billion in future milestones; U.S. profit and loss are shared equally and Vir holds a U.S. co-promotion option
  • Full-year 2025 revenue was $68.6 million versus $74.2 million in 2024; full-year net loss was $438.0 million, or $(3.16) per share, versus $522.0 million, or $(3.83) per share

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECFeb 23, 2026, 5:16 PM ET
Accession number0001628280-26-010740

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.